Neumora Therapeutics (NMRA) Other financing activities (2022 - 2023)
Neumora Therapeutics (NMRA) recorded quarterly Other financing activities of $820000.0 in Q4 2023, down 96.5% quarter-over-quarter from $23.5 million in Q3 2023, and up 498.06% on a YoY basis from $137110.4 in Q4 2022.
Neumora Therapeutics (NMRA) Other financing activities (2022 - 2023) Analysis & Trends
Neumora Therapeutics' Other financing activities history runs 2 years deep, the most recent figure standing at $820000.0 for Q4 2023.
- In Q4 2023, Other financing activities rose 498.06% year-over-year to $820000.0; the TTM figure through Dec 2023 stood at $24.4 million (changed N/A YoY), while the FY2023 annual figure was $3.8 million, up 411.29% from the prior year.
- Other financing activities was $820000.0 for Q4 2023 at Neumora Therapeutics, down from $23.5 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $23.5 million in Q3 2023 to a low of -$206000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Neumora Therapeutics | 320.17 Mn | 320.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 820,000.00 |
| Dec 31, 2023 | 820,000.00 |
| Sep 30, 2023 | 23.45 Mn |
| Sep 30, 2023 | 23.45 Mn |
| Jun 30, 2023 | 112,000.00 |
| Jun 30, 2023 | 112,000.00 |
| Mar 31, 2023 | 10,000.00 |
| Mar 31, 2023 | 10,000.00 |
| Dec 31, 2022 | -206,000.00 |
| Dec 31, 2022 | -206,000.00 |
| Sep 30, 2022 | 151,000.00 |
| Sep 30, 2022 | 151,000.00 |